Aspartic protease MCAP mutant with improved catalytic performance and application thereof

By mutating the 70th threonine position of MCAP protease to isoleucine, T70I was obtained, which solved the problem of insufficient stability of MCAP protease, and achieved the improvement of enzyme activity and stability under different conditions. It is suitable for industrial proteins Degradation and active peptide preparation.

CN119082091APending Publication Date: 2024-12-06JIANGSU UNIV OF SCI & TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411339127.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The insufficient stability of MCAP proteases limits its application value in food and other industries. Traditional chemical degradation methods cause damage to the biological activity of active peptides. Proteases lacking high stability and catalytic activity are used for the preparation of active peptides.

Method used

By mutating the 70th threonine position of MCAP of the MCAP to isoleucine, the mutant T70I was obtained, which improved its enzymatic activity and stability under different conditions and enhanced the substrate Affinity.

Benefits of technology

The relative activity of T70I is increased by 26.4%, the thermal stability is increased to 65℃, the half-life is extended by 38 minutes, and the catalytic vitality is increased by 13%, which has greater application potential in the fields of industrial production and medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082091A_ABST
    Figure CN119082091A_ABST
Patent Text Reader

Abstract

The invention relates to an aspartic protease MCAP mutant with improved catalytic performance and application of the aspartic protease MCAP mutant, the sequence of acidic aspartic protease wild type MCAP from Mucor circinelloides is taken as the basis, threonine at the 70th site is mutated into isoleucine, a protease mutant T70I is obtained, and the amino acid sequence of the protease mutant T70I is shown as SEQ ID NO.2. The invention further discloses a preparation method of the aspartic protease MCAP mutant with the improved catalytic performance and application of the aspartic protease MCAP mutant with the improved catalytic performance. The acidic aspartic protease is high in catalytic activity and excellent in stability under the industrial production condition, and has great application potential in the fields of industrial production, waste treatment, medicine production and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of bioengineering and protein engineering, and in particular to an aspartic protease MCAP mutant with improved stability and application thereof. Background Art

[0002] Proteases are a class of enzymes that can hydrolyze proteins. According to their optimal pH, they are divided into alkaline proteases, neutral proteases, and acidic proteases. Among them, aspartic proteases are named after the two aspartic acid residues involved in their catalytic process. Most aspartic proteases show optimal enzyme activity at low pH values ​​(pH 3-4) and have isoelectric points in the pH range of 3 to 4.5. Proteases are widely used and have advantages such as mild reaction conditions and green environmental protection. Therefore, proteases are widely used in food, chemistry, medicine, feed and other fields. At present, the main application of proteases is to use proteases to degrade natural proteins and obtain various active peptides. MCAP is an acidic aspartic protease from Mucor circinelloides. It has extremely high enzyme activity and wide substrate specificity. It has broad application potential in industrial production, waste treatment and medicine (Amb Express, 2018, 8(1):157). On the other hand, the stability of MCAP protease is greatly limited. Improving the catalytic performance of MCAP protease can help improve the practical application value of MCAP in industries such as food, and can also provide new ideas for the molecular improvement of aspartic protease.

[0003] Peptides are polymers formed by covalently linking two or more amino groups through peptide bonds. They are the most active, easily absorbed, and physiologically effective nutrients between macromolecular proteins and amino acids. They have multiple biological activities, including antibacterial, immunosuppressive, anti-tumor, antioxidant, anti-fatigue, hypoglycemic, hypotensive, and hypolipidemic functions (Biomolecules therapeutics, 2020, 28(1): 18-24). Active peptides have been widely used in the medical and food industries, for example (BioFactors. 2024, 50(1): 33–35). In the preparation of active peptides, traditional chemical degradation methods not only cause wastewater and waste gas pollution, but also damage the biological activity of peptides (Process Biochemistry, 2022, 122(2): 36-52), while enzymatic degradation is more environmentally friendly. On the other hand, the properties of the protease itself have a great influence on the protein degradation rate and the biological activity of the product polypeptide. Generally speaking, increasing the protein degradation rate of the protease can enhance the antioxidant and other biological activities of the product polypeptide (International Journal of Food Science and Technology, 2021, 56(11): 5904-5912). Therefore, proteases with high stability and catalytic activity are of great significance for protein degradation and the preparation of active polypeptides.

[0004] To date, a variety of protein engineering technologies have been applied to the molecular improvement of proteases, including rational design, directed evolution and other methods. By modifying the protease gene sequence to change its protein structure, the enzymatic properties of the protease, such as pH stability, thermal stability, catalytic activity, substrate specificity, product specificity and extreme environmental tolerance, have been improved. For example, the stability of alkaline protease was improved by introducing disulfide bonds, and its mutant increased its relative activity by 15.6% compared with the wild type after adding detergent (CN117487784A). The alkaline mutant that changed the conformation of the catalytic channel by optimizing the loop region had a t 1 / 2The activity of the enzyme increased to 39.7 times that of the parent, and the specific activity increased by 62% compared with the parent (CN116814593A). Directed evolution has been widely used in the molecular improvement of enzymes. For example, in terms of stability improvement, the half-life of the mutant obtained by directed evolution of Bacillus gibsoniialkaline protease at 60°C was extended by 100 times (Biotechnology and Bioengineering, 2013, 110 (3): 711-720). In terms of catalytic activity improvement, the multi-point mutant of keratin obtained by directed evolution is 2.1 times the activity of its wild type (CN114574469A). Rational design is to improve the catalytic performance of proteases by modifying sites based on structural design obtained by methods such as cryo-electron microscopy, while the molecular improvement method of directed evolution requires a lower degree of mastery of the protease structure, and is more suitable for MCAP, a protease that has been less studied. Summary of the invention

[0005] Technical problem to be solved: In response to the above technical problem, the present invention provides an acid aspartic protease MCAP mutant with improved catalytic performance and application thereof.

[0006] Technical solution: An acid aspartic acid protease mutant is based on the sequence of the wild-type acid aspartic acid protease MCAP from Mucor circinelloides, and the 70th threonine is mutated to isoleucine to obtain a protease mutant T70I, whose amino acid sequence is shown in SEQ ID NO.2.

[0007] The nucleic acid sequence encoding the amino acid of the protease mutant T70I is shown in SEQ ID NO.1.

[0008] A vector containing the nucleic acid shown in SEQ ID NO.1.

[0009] A host cell containing the above vector.

[0010] Application of the above aspartic acid protease mutant in the production of degraded proteins.

[0011] Application of the above strains in the production of degraded proteins.

[0012] The active peptide prepared by the above-mentioned aspartic acid protease mutant.

[0013] Application of the above host cells in the production of active peptides.

[0014] Application of the above active peptides in the preparation of food additives.

[0015] Beneficial effects: The present invention provides a mutant T70I of acidic aspartic protease MCAP with excellent properties and suitable for catalyzing protein degradation under industrial production conditions. The relative activity of T70I (93.2%) at pH 5 is 26.4% higher than that of MCAP (66.8%). The thermal stability of T70I is also improved. 50 The half-life at 60°C was increased from 60°C of the wild type to 71min, an increase of 38min. The catalytic activity of T70I was 13% higher than that of MCAP (5772.58 U / mg vs. 5128.43 U / mg). The molecular dynamics simulation results showed that the root mean square deviation curve of T70I stabilized faster than that of MCAP (10ns vs. 50ns). m The results show that the temperature of T70I is lower than that of wild-type enzyme (3.77 vs. 3.37), indicating that its rigidity is enhanced while its affinity for substrate is increased. The increase in the optimum temperature of T70I is conducive to the enzyme's better degradation function in industrial protein degradation; and the stability of T70I is improved to a certain extent compared with the wild-type enzyme. Such properties enable the enzyme to better resist enzyme inactivation caused by high-temperature degradation conditions. Such an acidic aspartic protease with high catalytic activity and excellent stability under industrial production conditions has great application potential in industrial production, waste treatment, and pharmaceutical production. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Protein gel images of MCAP and T70I; (lane 1: 120 kDa protein standard; lane 2: wild-type MCAP purified before Endo H treatment; lane 3: wild-type MCAP purified after Endo H treatment; lane 4: mutant T70I purified before Endo H treatment; lane 5: mutant T70I purified after Endo H treatment);

[0017] Figure 2 The optimum pH results of MCAP and T70I at 65°C;

[0018] Figure 3 The optimum temperature determination results of MCAP and T70I at pH 4;

[0019] Figure 4 The results of the thermal stability (half-life at 60°C) of MCAP and T70I are shown in Figure 2.

[0020] Figure 5 The results of pH stability tests of MCAP and T70I;

[0021] Figure 6The kinetic fitting results of MCAP and T70I; (A) MCAP; (B) T70I. DETAILED DESCRIPTION

[0022] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.

[0023] 1. Strains and vectors: The expression host is Pichia pastoris GS115, and the expression plasmid vector pPIC9r is prepared in the laboratory;

[0024] 2. Enzymes and other biochemical reagents: DMT competent Escherichia coli and restriction endonuclease BglⅡ were purchased from Quanshijin Company, ampicillin was purchased from Solebao Biochemical Reagents, and casein was purchased from Sigma-Aldrich Company; other reagents were domestic analytical grade reagents (all purchased from Sinopharm Group);

[0025] 3. Culture medium:

[0026] (1) LB liquid medium: 0.5% yeast extract, 1% peptone, 1% NaCl, pH 7.0;

[0027] (2) YPD liquid medium: 1% yeast extract, 2% peptone, 2% glucose;

[0028] (3) MD solid medium: 2% glucose, 1.5% agarose, 1.34% YNB, 0.00004% Biotin;

[0029] (4) BMGY medium: 1% yeast extract, 2% peptone, 1% glycerol (V / V), 1.34% YNB, 0.00004% Biotin;

[0030] (5) BMMY medium: 1% yeast extract, 2% peptone, 0.5% methanol (V / V), 1.34% YNB, 0.00004% Biotin.

[0031] Example 1 Construction of MCAP mutant plasmid

[0032] Taking the acidic aspartic protease MCAP from Mucor circinelloides as the starting material, the MCAP gene fragment was ordered from Tianlin Bio and connected to pPIC9r, heat-shocked and transformed into DMT competent Escherichia coli cells, coated with ampicillin-resistant LB solid medium plates, single colonies were picked for sequencing, and the positive clones were preserved. The positive clones were inoculated into liquid LB medium for expansion, the wild-type MCAP plasmid was extracted, the protease was mutated by directed evolution, the thermosensitive amino acid sites affecting the stability of MCAP protease were screened and mutations were designed, and the primers are shown in Table 1. The preliminary screening results of the thermal stability of MCAP and its mutants are shown in Table 3. The residual activity of most mutants compared with the untreated control group after 30 minutes in a water bath at 60°C was close to that of the wild-type MCAP, and the residual relative activity of T70I with the largest increase was 70.82%, which was 22% higher than the wild-type 48.21%, greatly improving the thermal stability of MCAP protease, meeting the industrial application requirements of food and feed.

[0033] Example 2 Preparation of T70I mutant with improved catalytic performance

[0034] The mutant T70I plasmid obtained in Example 1 was heat-shocked and transformed into DMT competent E. coli cells, and LB solid medium plates with ampicillin resistance were coated. Single colonies were picked for sequencing, and the positive clones were preserved. The T70I mutant recombinant plasmid was extracted and electroporated to transform Pichia pastoris GS115 to obtain a recombinant yeast strain. The enzyme activity at 60°C was screened using a high-throughput screening plate to obtain a mutant with improved stability compared to the wild type.

[0035] The recombinant GS115 strain with improved activity was inoculated into a 2L Erlenmeyer flask with 300mL BMGY medium and cultured for 48h; the precipitate after centrifugation was resuspended in 300mL BMMY medium containing 0.5% methanol and induced with methanol. 0.5mL methanol was added every 12h to keep the methanol concentration in the bacterial solution at 0.5%. After 48h of culture, the supernatant was centrifuged and used for enzyme activity detection.

[0036] Example 3 Activity analysis of the MCAP-T70I mutant with improved catalytic performance

[0037] 1. Determination of protease activity

[0038] According to the national standard method (GB / T 23527-2009), 1% (w / v, g / mL) casein was used as the substrate to determine the activity of the protease. The specific method is as follows: Under the given pH and temperature conditions, 2mL of the reaction system includes 1mL of enzyme solution and 1mL of substrate, and the reaction is carried out for 10min. 2mL of 0.4mol / L trichloroacetic acid is added to terminate the reaction, and the supernatant is taken by centrifugation. 5.0mL of 0.4mol / L sodium carbonate solution is added to adjust the pH, and 1.0mL of Folin reagent is added. The color is developed at 40°C for 20min. 200μL of the supernatant is taken and the OD value is measured at 680nm. The protease activity unit (U) is defined as the amount of enzyme required to hydrolyze casein to generate 1μmol of tyrosine per minute under the above conditions.

[0039] 2. Determination of the enzymatic properties of the T70I mutant with improved catalytic performance

[0040] 1. The optimal pH of wild-type MCAP and mutant T70I with improved catalytic performance was determined as follows:

[0041] The wild-type MCAP and mutant T70I purified in Example 2 were reacted at different pH values ​​to determine their optimal pH values. The substrate (casein) was dissolved in 0.2 mol / L citric acid-sodium hydrogen phosphate buffer at different pH values ​​and the protease activity was determined at 60°C. Figure 2 The results of the determination of the optimal pH are shown. The optimal pH values ​​of MCAP and T70I are both 4.

[0042] 2. The optimum temperatures of wild-type MCAP and mutant T70I with improved catalytic performance were determined as follows:

[0043] The enzymatic reaction was carried out at 40-80°C with 5°C intervals using wild-type MCAP and T70I in a sodium dihydrogen phosphate-disodium hydrogen phosphate buffer system at an optimal pH (pH 4) of 0.2 mol / L with casein as substrate. Figure 3 The results of the optimal temperature determination were shown. The optimal temperatures of MCAP and T70I were 60°C and 65°C, respectively. The optimal temperature of T70I was 5°C higher than that of the wild-type MCAP, and its stability was significantly improved.

[0044] 3. The half-life stability of wild-type MCAP and mutant T70I with improved catalytic performance at 60°C was determined as follows:

[0045] The stability-enhanced T70I mutant and wild-type MCAP were sampled at 60°C at 5-minute intervals for 1 h. The residual activity was then measured at pH 4 and 65°C using casein as a substrate. The half-life measurement results at 60°C are shown in Figure 2. Figure 4 As shown, the t of T70I 1 / 2The activity of wild-type MCAP and mutant T70I gradually decreased after a certain period of incubation, but the T70I mutant with improved stability had higher residual activity and performed better than the wild type.

[0046] 4. Kinetics of wild-type MCAP and mutant T70I with improved catalytic performance were determined as follows:

[0047] Under optimal conditions, kinetic parameters and specific activities of wild-type MCAP and mutant T70I were determined with 1% (w / v, g / mL) casein as substrate. The fitting curves and results are shown in Figure 5 and as shown in Table 2. The kinetic assay results showed that under the optimal conditions, the K m and V max The K of wild-type MCAP is 3.37 mg / mL and 7942 U / ·mg respectively. m and V max The k of T70I mutant was 3.77 mg / mL and 7500 U / mg respectively. cat / K m It is 1.18 times that of wild-type MCAP. In addition, the results of enzyme property determination showed that the specific activity of mutant T70I under optimal conditions (5772.6U / mg) was 13% higher than that of wild-type MCAP (5128.4U / mg). Compared with wild-type MCAP, mutant T70I has improved stability, catalytic efficiency and substrate affinity.

[0048] In summary, the mutant T70I with improved catalytic performance has improved enzyme activity and stability at higher temperatures compared to the wild-type MCAP, making it a more suitable biocatalyst for processing protein biomass and providing new materials for enzymatic processing of proteins.

[0049] Table 1 Primer design for MCAP point mutation

[0050]

[0051]

[0052] Table 2 Kinetic parameters of MCAP-T70I mutant and wild-type MCAP

[0053]

[0054] Table 3 Preliminary screening results of thermal stability of MCAP and its mutants

[0055]

[0056] *After incubation at 60°C for 30 min in a water bath, the residual activity of the wild-type MCAP and its mutants was measured compared with the untreated control.

Claims

1. An acid aspartic acid protease mutant, characterized in that: From Mucor circinelloides Mucor circinelloides ) was used as a basis for the sequence of the wild-type acid aspartic protease MCAP, and the threonine at position 70 was mutated to isoleucine to obtain the protease mutant T70I, whose amino acid sequence is shown in SEQ ID NO.

2.

2. The acid aspartic acid protease MCAP mutant according to claim 1, characterized in that: The nucleic acid sequence encoding the amino acid of the protease mutant T70I is shown in SEQ ID NO.

1.

3. A vector containing the nucleic acid shown in SEQ ID NO.

1.

4. A host cell containing the vector according to claim 3.

5. Use of the aspartic acid protease mutant according to claim 1 in the production of degraded proteins.

6. Use of the strain according to claim 4 in the production of degraded proteins.

7. An active peptide prepared from the aspartic protease mutant according to claim 1.

8. Use of the host cell according to claim 4 in the production of active peptides.

9. Use of the active peptide according to claim 7 in the preparation of food additives.

Citation Information

Cited By

  • Aspartic protease mutant and application thereof

    CN119931997A